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Based on striking parallels between the cell kinetics in the epidermal lesion ofpsoriasis and the
proliferation of hair matrix keratinocytes during the anagen phase of the hair growth cycle, the
hypothesis is proposed that both phenomena may share the same "switch-on" mechanism.
Particular emphasis is placed on a comparison between the Koebner phenomenon in psoriasis and
wounding-induced anagen hair growth. In discussing alternative theoretical models for the
proposed common "switch-on" mechanism, some useful experimental tools are suggested.
Research into the mechanisms which control epithelial proliferation in psoriasis and hair growth
may provide new insights into other growth processes, such as embryonic organogenesis and
neoplasia, in which similar epithelial-mesenchymal interactions play a pivotal role.
Psoriasis, one of the most common skin diseases of man, and the growing (anagen)
hair follicle provide unique models for the study of epithelial-mesenchymal interac-
tions. Both exhibit an intricate and still imperfectly understood interplay of epithelial
and mesenchymal elements (epidermis/dermis and hairbulb/dermal papilla), which is
characterized by a state of increased epithelial proliferation. This interplay results in
the typical psoriatic plaque and the formation ofa new hair from keratinized hair bulb
cells, respectively.
On the surface, hair growth and psoriasis hardly seem interrelated since psoriasis
does not usually interfere with hair growth [1]. On closer inspection, however, some
interesting analogies between the initial epidermal lesion ofpsoriasis and the prolifera-
tion ofhair matrix keratinocytes during thegrowth phaseofthe haircycleare revealed.
It is tempting to speculate that a common underlying "switch-on" mechanism may
exist for both systems.
The hair follicle undergoes a cyclic pattern of growth, passing through a growth
phase (anagen), a degeneration phase (catagen), a resting phase (telogen), and finally
returning to the growth phase. The "developmental revolution" which leads from a
small, apparently unorganized cell cluster of telogen germ into the well-organized
early anagen follicle [2] exhibits both one of the fastest patterns of cell prolifera-
tion found in normal human tissues and a negligibly small Go population [3]. This
proliferation pattern is in striking accordance with the cell kinetics oflesional psoriatic
skin: greatly increased mitotic activity in two or three basal cell layers with a growth
fraction of reportedly 100 percent [4] supports the pathognomonic epidermal hyper-
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proliferation of psoriasis, a condition which combines both the growth characteristics
of a benign tumor and a seemingly stable equilibrium of cell proliferation and loss
[5].
The calculated cell cycle times of 36-38 hours for psoriasis [6] and 38.8 hours for
human scalp hair matrix [3] only further emphasize the similarities between psoriasis
and hair growth (although there is some disagreement on the actual cell cycle time in
psoriasis [7]). One really wonders why neither the very rapidly dividing cells ofthe hair
bulb nor the hyperproliferating epidermis in psoriasis show an increased incidence of
malignancy. What is the regulatory system which turns on such a high rate of
proliferation without losing control? Evidently, a better understanding of epithelial-
mesenchymal interplay in psoriasis and hair growth, particularly its "switch-on"
mechanism, would be of profound interest not only to dermatologists but also to
developmental biologists and oncologists.
Apart from the correlation in cell kinetics, a number of clinical and experimental
findings, as well as some theories concerning growth regulation, lend credence to the
hypothesis that a common "switch-on" mechanism governs epithelial proliferation in
both the anagen follicle and the psoriatic lesion.
The withdrawal ofcorticosteroid therapy is known to induce psoriatic efflorescences
[8], and steroids can produce symptomatic hypertrichosis [9]. Steroids applied to
psoriatic lesions also produce a fast remission [10] and may be applied in pathologic
conditions involving hair loss, such as alopecia areata, for hair regrowth [9,11]. Other
drugs affecting both psoriasis and hair growth include the psoralens, cyclosporin A
(CsA), bromocriptine, and anthralin. Psoralens are among the standard repertoire in
psoriasis treatment [e.g., as psoralen plus ultraviolet A light (PUVA) therapy] and can
occasionally induce hypertrichosis [9]. One of CsA's most common side effects is a
dose-dependent hypertrichosis [12], whereas at the same time its effectiveness in the
treatment of psoriasis has increasingly become appreciated [13,14]. In addition,
experimental hair growth induction by CsA administration in nude mice [15,16] and
hair regrowth in one patient with alopecia areata by topical application of CsA [17]
make this drug a fascinating tool for parallel research into psoriasis and hair biology.
The dopaminergic agonist bromocriptine has been described as useful in the treatment
ofhirsutism due to hyperprolactinemia [9] as well as in the treatment ofpsoriasis [18].
Finally, anthralin (dithranol) is a highly effective agent for topical treatment of
psoriatic lesions [10]. Recently, it has also been shown to induce terminal hair
regrowth in some patients with alopecia areata [19].
Likewise, ultraviolet (UV) light affects both hair growth and psoriasis. Not only is
UV light among the most widely applied therapeutic regimens for psoriasis (Goecker-
man therapy, PUVA, and so on) [10], but it has also been successfully applied to
induce hair regrowth in alopecia areata (PUVA) [11] and to induce anagen in
marsupials [20]. Hypertrichosis is a documented side effect of PUVA treatment [21]
and UV light can, on occasion, trigger psoriatic lesions, in the form of a Koebner
phenomenon [22] (i.e., the development of isomorphic pathologic lesions in the
traumatized uninvolved skin of patients with cutaneous disease [25]).
In summary, all these exogenous agents-whether they exert a positive or negative
effect on psoriasis and hair growth-are likely to interfere with the regulatory pathway
responsible for initiating or inhibiting epithelial proliferation. Reverse effects of a
given agent on psoriatic epidermis and hair follicles could easily be explained by the
respective differences in targets for this agent (receptors, cell population, cell metabo-
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lism, and the like). Thescalp-with about 85 percent ofhair follicles in anagen-is the
most frequently involved site ofpsoriasis [23], and the interfollicular epidermis in the
scalp of psoriatics shows a threefold greater rate of proliferation than controls [24].
This fact could be indicative of a lowered threshold for development of the psoriatic
epidermal hyperproliferation in the scalp, due to the presence of factors maintaining
the high level ofhair growth in this area.
KOEBNER PHENOMENON AND WOUNDING-INDUCED ANAGEN
Initiation and inhibition of epidermal proliferation can, in our context, most
profitably be studied in the Koebner phenomenon, and plucking or stripping induced
anagen hair growth in rodents. Especially in psoriasis, it has long beenappreciated that
mechanical traumatization of the skin can lead to the appearance of lesions in
previously uninvolved skin [26]. On the other hand, resting hair follicles can almost
invariably be induced to enter the growth phase by traumatizing them [27] (e.g.,
plucking ofrat vibrissae follicles, stripping oftelogen mice with wax/rosin).
Ifwhat we hypothesize holds true, then a traumatizing stimulus that induces one of
these two phenomena should, in theory, also becapableofinducing theother. The fact
that mechanical trauma, as well as UV light, is a potent inducer ofboth the Koebner
phenomenon in psoriasis and hair growth [11,22] certainly supports our proposal for a
common "switch-on" mechanism. Thus, the Koebner phenomenon and the wounding-
induced anagen follicle could serve as clean and predictable vehicles for evaluating
hypotheses concerned with characterizing the regulatory mechanism for growth
induction and inhibition.
The most important conclusion arising from our postulate, however, is that a
research approach should be pursued which integrates data from psoriasis research
with that from investigation into hair biology. It may be highly rewarding to study
carefully the effects of agents, which have been implicated with the initiation of the
psoriatic epidermal lesion, on the induction/inhibition ofhair growth. Likewise, drugs
which have proven clinically useful or experimentally interesting in one of these two
fields should systematically be assessed for their actions in the other. This integrated
research approach may lead to new therapeutic strategies for the treatment of
psoriasis, other skin diseases characterized by a disorder of epidermal proliferation,
and hair disease.
STIMULATION VERSUS DISINHIBITION
In pursuing this approach we must keep in mind that, to date, not even the most
fundamental aspects of the regulatory processes underlying epidermal/hair growth
have been answered satisfactorily. Two contrasting hypotheses explain interference
with the inherent control mechanisms of epidermal/hair matrix proliferation, which
can be summarized under the heading "stimulatory signal versus disinhibition." There
is evidence for the presence of both types ofcontrol, whose relative effect in epithelial
tissues yet awaits further elucidation.
Chase [28] hypothesized that the stimulus for the initiation of follicle activity may
be the loss ofan inhibitor ofproliferation, whosegradual build-upduring anagen would
lead to the resting stage of the growth cycle. Gradually being used up or dispersed
during telogen or removed by wounding of the follicle (plucking/stripping), the now
disinhibited epithelium would resume proliferation. Although it has been argued that
repeated plucking-contrary to Chase's disinhibition hypothesis-does not lead to
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continuous growth activity of the hair follicle [29], other important findings support
Chase's theory: Bullough et al. [30] have isolated an "epidermal chalone," which is
thought to inhibit epidermal mitotic activity at the level of gene expression [31] and
could be envisaged as a candidate for Chase's postulated inhibitor. More recently,
Elgjo et al. have purified from mouse skin a pentapeptide that inhibits epidermal
mitosis in mice [32], inhibits proliferation, and enhances terminal differentiation of
cultured mouse epidermal cells [33], thus lending further credence to the pioneering
concept ofdisinhibition.
A similar mechanism has been proposed for the initiation ofthe psoriatic lesion via a
loss of normal epidermal proliferation control [34]. This hypothesis suggests a
defective inhibitory system. The newer immunological concepts of the etiology of
psoriasis are ofparticular interest in this context, since they also integrate the concept
of a stimulatory signal which may override the prevailing suppressor influences for
proliferation. One recent theory depicts psoriasis as a T-helper lymphocyte-mediated
disease in which hyperproliferation of keratinocytes is mediated by a number of
cytokines, released by interacting T-helper and Langerhans cells in response to a
putative "psoriatic antigen," insufficiently controlled by the normally dominant sup-
pressor mechanisms [35].
This theory, of course, immediately raises the fascinating possibility that similar
immunological interactions may play a substantial role in the "switch-on" mechanism
for anagen hair growth. Unfortunately, however, the immunology ofthe hair follicle is,
at present, almost completely obscure, so that a more thorough understanding of hair
follicle immunology is a prerequisite for this tempting speculation. The profound
differences of "inflammatory" parameters (mast cells, histamine, serotonin) during
the rat hair cycle [29] strongly point toward further investigation into the immunology
ofthe hair follicle.
With respect to the induction of anagen, it has been suggested that a stimulatory
signal rather than disinhibition causes increased mitotic activity, especially in wound-
ing-induced anagen, where it has been proposed that some local product ofinjured cells
("wound hormone") may provide this signal for proliferation induction (e.g. [36]).
Under physiologic conditions, this signal could be released from the dermal papilla (as
Van Scott et al. have suggested [37]), whose presence has been demonstrated to be
essential for anagen induction [38,39]. In further support of the stimulation hypothe-
sis, the description of epidermal growth factor (EGF), an epidermal growth- and
keratinization-promoting polypeptide [40], and EGF receptors in rat hair follicles [41]
could be cited; however, the precise role of EGF in the regulation of epidermal
proliferation and hair growth awaits clarification.
Correspondingly, a host of stimulatory signals has been implicated in the primary
stage ofthe psoriatic epidermal hyperproliferation: cyclic nucleotides, prostaglandins,
leukotrienes, polyamines, phosphalipase A2, ornithine decarboxylase, the protease-
antiprotease system, and various cytokines are all known to have an effect on the
regulation of epidermal proliferation and have attracted particular attention in
psoriasis [42]. It would now seem mandatory to analyze carefully the effects of these
supposed regulatory agents on anagen induction.
Irrespective of the probably dominant intrinsic control apparatus of cell prolifera-
tion in hair growth and psoriatic epidermis, systemic factors are also operative which
may potently modify the proposed inhibition/disinhibition signal (e.g., influence of
steroid and thyroid hormones on hair growth [43,44] and triggering or exacerbation of
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psoriasis by infection and stress [10,22]). These influences, extrinsic to the skin,
demand a clear-cut model to study their relative importance in comparison with any
intrinsic regulatory mechanism of epithelial proliferation. In probing this relation, as
well, the Koebner phenomenon and wounding-induced anagen seem to be the most
promising areas for study and comparison.
A few practical approaches with which our hypothesis of a common "switch-on"
mechanism in psoriasis and anagen hair growth could be tested are described below.
CYCLOSPORINE AND CYTOKINE PRODUCTION
Perhaps the most interesting experimental agent for a joint study of psoriasis
pathogenesis and hair growth regulation is cyclosporine A (CsA), whose effectiveness
in both suppressing the psoriatic epidermal lesion and inducing hair growth has
previously been mentioned. Our growing insight into the still imperfectly understood
action ofthis immunosuppressive drug mayvery well serve to reveal general regulatory
principles governing the induction ofepithelial proliferation.
Since we have come to understand the skin as an active immunomodulating organ
[14,45,46], the notion that CsA inhibits the production of a variety of cytokines,
including interleukin 1 (IL-1), interleukin 2 (IL-2), interleukin 3 (IL-3) and gamma
interferon (IFN-'y) in mononuclear cells and macrophages [47,48], makes CsA an
attractive experimental tool for interfering with the regulatory loops of the skin
immune system. These regulatory loops have already been shown to exert considerable
influence on keratinocyte proliferation (e.g., via IL-1, epidermal proliferation factor
[EPF], and epidermal thymocyte activating factor [ETAF] [49]), particularly in
psoriasis [14,35]. Do these CsA-inhibited cytokines also regulate anagen?
It is believed that CsA inhibits the synthesis of cytokine mRNA, particularly
inhibiting IL-2 gene transcription [50]. Hess and Colombani have suggested that CsA,
which is known to bind to thecytosol proteins calmodulin and cyclophilin [51,52], may
block calmodulin-dependent mRNA transcription [53]. In addition to being useful in
psoriasis research [54], calmodulin antagonists, such as anthralin and miconazole,
should then be highly interesting experimental tools in the study of hair growth
regulation: do they antagonize or enhance CsA-induced hair growth? Are these
calmodulin inhibitors able to stimulate hair growth on their own? (In alopecia areata,
topical anthralin seems to induce terminal hair regrowth in some patients [19].) Ifso,
is CsA-induced anagen induction a calmodulin-mediated process?
Although, certainly, the whole repertoire ofcytokines influenced by CsA (including
IL-1, IL-2, IL-3, IFN--y, transforming growth factor alpha [TGF-a]/EGF, transform-
ing growth factor beta [TGF-j3], and possibly others) deserves systematic study, IL-2
seems to be an especially rewarding candidate for further examination, since the
effects ofCsA on IL-2 production arealready documented by a wealth ofdata [47,53].
In addition, recent reports suggest a strongly synergistic effect of CsA and anti-IL-2
receptor antibodies (e.g., [55]).
The demonstration ofCsA-induced hair growth in vivo [12,15-17] leaves us with a
number ofalternative theories, whose verification would mean a decisive leap forward
in our understanding ofhair growth regulation.
CsA may inhibit the production of an anti-proliferation protein (possibly disinhi-
bition ofanagen by inhibition of IL-2, interferon alpha/beta [IFN-a/,3], TGF-3).
CsA could simulate the effects of a stimulatory "switch-on" molecule for anagen
growth (perhaps IL-1).
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Hair growth induction by the immunosuppressant CsA indicates an important
and so far unappreciated role for the hair follicle immune system in the regulation of
hair growth.
CsA's mechanism ofaction on thecytosol and intranuclear level may besimilar to
that ofthe anticipated regulatory protein(s) ofhair growth.
PHOSPHOLIPASE A2, PROSTAGLANDINS, AND LEUKOTRIENES
Phospholipase A2 is an important regulatory step in the production of prostaglan-
dins and leukotrienes by its release of arachidonic acid from cell membranes [56].
Interestingly, CsA can inhibit phospholipase A2 [57] (via calmodulin perhaps). This
enzyme is significantly increased in non-lesional psoriatic epidermis [58]-as is the
phospholipase activator calmodulin [59]. Therefore, hyperactivity of the calmodulin-
phospholipase A2 system is a strong candidate for explaining a primary metabolic
defect as an essential component of the "switch-on" mechanism of epidermal hyper-
proliferation in psoriasis as well as for explaining hair growth induction. The ab-
normalities of leukotriene and prostaglandin concentration in psoriatic epidermis
(especially ofleukotriene B4 [LTB4] and prostaglandin E2 [PGE2] [42]), could then
well be understood as the (secondary) mediating system which provides a strong
stimulus for cell proliferation. Studies assessing the effect ofdifferent eicosanoids and
inhibitors ofcyclooxygenase and 5-lipoxygenase on hair growth should help to clarify
this intriguing possibility.
PROLACTIN AND BROMOCRIPTINE
Hyperprolactinemia is one of the causes of hirsutism and has been treated
successfully with bromocriptine [9]. At least in women, increased hair loss is a known
side effect ofbromocriptine therapy [60], which profoundly lowers prolactin levels via
its dopaminergic agonism (dopamine inhibits the hypophyseal release of prolactin)
[61]. Bromocriptine, in turn, has been reported to be an effective drug for the
treatment of psoriatic lesions [18]. The authors thought this result to be due to an
inhibitory effect ofbromocriptine on growth hormone release. This hypothesis and the
use of bromocriptine as a therapeutic regimen in psoriasis, however, have not been
generally accepted [62,63,64]. In the light of CsA's effectiveness in psoriatic lesions
[14], the finding that CsA and prolactin compete for binding to a common receptor
and that CsA's mechanism of action may even be mediated via its antagonism of the
prolactin receptor [65,66], it is reasonable to assume that the effects of bromocriptine
on psoriasis are, in fact, due to this drug's potency for lowering serum prolactin levels.
This assumption makes prolactin and bromocriptine another interesting pair of
research tools; is prolactin involved in the induction of epithelial proliferation in
psoriasis and hairgrowth (where its effect, at leastclinically, is manifested in hirsutism
in patients with hyperprolactinemia), and can its effect be antagonized by bromocrip-
tine?
It could well be possible that prolactin plays an important role in the extrinsic
control of epithelial proliferation via the hypothalamic-hypophyseal axis. Such an
assumption would, on the one hand, help to explain why stress-a well-documented
stimulus for prolactin release [61 ]-can trigger or exacerbate psoriasis [22]. On the
other, it would account for the finding that cooperation of hypophyseal hormones
seems to be important for androgen effect on and responsiveness of hair follicles as
peripheral targets of these hormones [43]. To carry this speculation even further, the
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immunomodulatory properties ofprolactin [65,67] may designate this hormone to be a
crucial messenger on the neuroimmune axis for the achievement of central nervous
system modulation ofepithelial proliferation and skin immune parameters.
Polyamines (putrescine, spermidine, and the like) are closely associated with cell
proliferation and have been found to be increased in lesional and non-lesional skin of
psoriatics (with ornithine decarboxylase [ODC] as rate-limiting enzyme for the
polyamine synthesis) [42]. Likewise, ODC shows significantly higher concentrations
in anagen hair than in telogen hair [68], and pluckingofrathairs induces high levelsof
ODC [43]. In light of Larsson's hypothesis that prolactin and other peptide hormones
exert their effect on DNA and protein synthesis via the induction of ODC and that
CsA antagonizes this prolactin induction of ODC [65], a closer analysis of the
polyamine biosynthetic pathway, with respect totheproposed "switch-on" mechanism,
seems worthwhile.
Study of the protease-antiprotease system, which seems to be involved in growth
regulation ([69], in psoriasis [42,70,71]), may be even more profitable in elucidating
the proposed common "switch-on" mechanism. The increased activity ofplasminogen
activator in lesional and non-lesional psoriatic epidermis [70]-apparently correlated
with the disease activity [72]-has prompted some researchers to propose that the
protease-antiprotease equilibrium in the epidermis could well be a contributing
component to Bullough's "epidermal chalone" and an abnormal proteolytic activity in
the epidermis could account for the induction ofthe psoriatic epidermal hyperprolifer-
ation [71]. It would be most interesting to learn whether wounding-induced anagen
hair growth is also associated with a higher activity of plasminogen activator, and
whether this class ofserine proteases can induce anagen on its own.
CONCLUSION
Based on striking parallels between the epithelial cell kinetics in the psoriatic
epidermal lesion and anagen hair growth, we have proposed the hypothesis that both
states of increased epithelial proliferation may share a common "switch-on" mecha-
nism. This conclusion is supported by distinct clinical and experimental evidence.
Therefore, the pathogenesis of psoriasis and the regulation of hair growth should no
longer be approached isolated from each other. Instead, the systematic exchange of
data and ideas between these two fields ofdermatologic research is advocated. Specific
pharmacological investigations may prove particularly valuable in the pursuit of this
new integrated research approach with its interesting therapeutic implications. In
addition, investigations into the regulatory mechanisms which govern epithelial
proliferation in psoriasis and hair growth may aid in furthering our understanding of
other growth phenomena, such as neoplasia and embryonic organogenesis, in which
similar epithelial-mesenchymal interactions play important roles.
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